HIMS Headwinds Ahead of Earnings

Core Viewpoint - Hims and Hers is facing significant regulatory challenges, including a lawsuit with Novo, which has contributed to a 54% decline in stock price since the start of 2026. Despite these challenges, the underlying fundamentals of the business remain strong, and the upcoming earnings call is crucial for providing clarity on future growth expectations and regulatory issues [2][4][21]. Regulatory Concerns - The company is currently dealing with regulatory scrutiny from the FDA and DOJ, particularly regarding its compounded semaglutide process, which poses a risk to its growth expectations [5][7]. - The lawsuit with Novo could result in substantial financial implications, potentially costing Hims and Hers between $1 billion to $2 billion if it goes to trial, although a settlement is anticipated [6][10]. Revenue and Growth Projections - Approximately 25% of Hims and Hers' revenue is estimated to come from compounded semaglutide, which could be significantly impacted by regulatory outcomes [6]. - The company is projected to generate around $2.3 billion to $2.4 billion in revenue this year, with a potential loss of $700 million if compounded semaglutide sales are eliminated [12][11]. - New verticals such as hormonal treatments, lab testing, and international expansion are expected to offset potential losses from GLP-1 sales, with the core business still showing 10% to 20% year-over-year growth [9][16][13]. Market Position and Strategy - Hims and Hers is not solely a GLP-1 company; it offers a broader healthcare platform that includes preventative care and treatment for existing conditions, which is a key distinction for investors [18][20]. - The company has strong gross margins in the mid-70s, providing flexibility to navigate uncertainties and invest in new growth areas [13][14]. - The market perception of Hims and Hers may shift as investors recognize its diversified business model beyond GLP-1 products, similar to how Amazon evolved beyond being just a bookstore [20][21].